Systemic sclerosis & Raynaud's
Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease
Authors' conclusion
Severe SSc-ILD and major deteriorations in lung function have important impacts on HRQoL.
Study context
- Population
- Patients with SSc-ILD in the SENSCIS trial (nintedanib or placebo, arms aggregated)
- Comparison
- Forced vital capacity (FVC) <70% predicted vs FVC ≥70% predicted
- Primary endpoint
- Associations of PRO measures (SGRQ, FACIT-Dyspnoea, HAQ-Disability Index (HAQ-DI) incl. SHAQ VAS) with SSc-ILD severity
- Follow-up
- Baseline and week 52
Methodological detailstreatment arms aggregated
- Treatment arms aggregated
Primary result
As reported in the abstract
SGRQ score · week 52
FVC <70% predicted
45.1
FVC ≥70% predicted
34.0
P < 0.0001
Further findings
| Outcome | FVC <70% predicted | FVC ≥70% predicted | P value |
|---|---|---|---|
| FACIT-Dyspnoea score · week 52 | 48.9 | 44.5 | P < 0.0001 |
| HAQ-DI score · week 52 | 0.7 | 0.6 | P < 0.0228 |
| SHAQ VAS breathing problems · week 52 | 3.6 | 2.6 | P < 0.0001 |
dcSSc and other SSc-ILD severity characteristics
- Worse patient-reported outcome (PRO) scores with dcSSc and other characteristics of SSc-ILD severity
Oxygen requirement or >30% fibrosis on HRCT at baseline · week 52
- Worse PRO scores at week 52
Major (>10%) improvement/worsening in FVC and PRO change · 1 year
- Corresponding improvement/worsening in SGRQ and other PROs; significant for SGRQ symptom domain
- P < 0.001
Original publication
Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford). Published 31 May 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →